Search results
Results from the WOW.Com Content Network
Dr Adrian James, president of the Royal College of Psychiatrists, said: “We know that antidepressants can save lives, and most people will not need to take them for more than six to 12 months ...
Benzodiazepine withdrawal syndrome (BZD withdrawal) is the cluster of signs and symptoms that may emerge when a person who has been taking benzodiazepines as prescribed develops a physical dependence on them and then reduces the dose or stops taking them without a safe taper schedule.
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
“We [as providers] want you to come off of meds in a way that feels good to you, doesn’t make you feel worse, and doesn’t make you think falsely that you need the medicine and can’t ...
Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. [13] It is also sometimes used off-label for treatment of chemotherapy-induced nausea and vomiting [ 14 ] and as an appetite stimulant . [ 15 ]
New research suggests that slowly tapering off GLP-1 drugs like Ozempic and Wegovy while adopting lifestyle changes may help prevent rebound weight gain.
Drug withdrawal, drug withdrawal syndrome, or substance withdrawal syndrome [1] is the group of symptoms that occur upon the abrupt discontinuation or decrease in the intake of pharmaceutical or recreational drugs.
Off-label promotion, kickbacks: Risperdal, Invega, Nesiritide: False Claims Act, FDCA 2012 Abbott Laboratories [8] $1.5 billion Off-label promotion Depakote: False Claims Act, FDCA 2009 Eli Lilly [9] $1.4 billion Off-label promotion Zyprexa: False Claims Act, FDCA 2001 TAP Pharmaceutical Products [10] $875 million Medicare fraud, kickbacks Lupron